Board of Trustees of Dartmouth College

Board Announces Removal of Merger Proposal from Annual Meeting Agenda

Retrieved on: 
Friday, September 29, 2023
Banking, Asset Management, Professional Services, Finance, NVG, Board of Trustees of Dartmouth College, Nuveen, Indian Sugar Mills Association, Trustee, NYSE, NQP, Security (finance)

The Boards of Trustees of Nuveen Pennsylvania Quality Municipal Income Fund (NYSE: NQP) and Nuveen AMT-Free Municipal Credit Income Fund (NYSE: NVG) announce the removal of a previously approved merger proposal from the funds’ upcoming annual meeting agenda.

Key Points: 
  • The Boards of Trustees of Nuveen Pennsylvania Quality Municipal Income Fund (NYSE: NQP) and Nuveen AMT-Free Municipal Credit Income Fund (NYSE: NVG) announce the removal of a previously approved merger proposal from the funds’ upcoming annual meeting agenda.
  • The Boards of Trustees considered current market conditions and other relevant considerations for each fund in assessing whether to move forward with the proposed merger.
  • It was determined that the proxy solicitation process and its associated costs would not be in the best interests of shareholders, therefore resulting in the removal of this proposal from the upcoming annual shareholder meeting agenda.
  • The funds offer exposure to a broad range of asset classes and are designed for income-focused investors seeking regular distributions.

Thorne Research, Inc. Loses Patent Challenge Decision, Upholding ChromaDex’s Intellectual Property Held Under Exclusive License From Dartmouth College

Retrieved on: 
Monday, August 15, 2022
Biotechnology, Health, Science, Pharmaceutical, Research, FDA, Securities Act of 1933, Risk, Board of Trustees of Dartmouth College, New York District Court, Therapeutic Goods Administration, Growth, SEC, PTAB, Patent, Security (finance), Research, NR, History, Annual report, Marketing, NAD, Company, COVID-19, Dartmouth College, Ageing, TGA, Health Canada, NASDAQ, An Act to exempt a particular class of securities from the Securities and Exchange Act, Trustee, Royal commission, ChromaDex, European Commission

ChromaDex holds an exclusive license to the 807 patent for compositions including nicotinamide riboside (NR) from the Trustees of Dartmouth College.

Key Points: 
  • ChromaDex holds an exclusive license to the 807 patent for compositions including nicotinamide riboside (NR) from the Trustees of Dartmouth College.
  • ChromaDex is the exclusive supplier of nicotinamide riboside chloride, Niagen, a novel form of NR backed by 20 published and peer-reviewed clinical trials.
  • The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age.
  • Nicotinamide riboside and other NAD+ precursors are protected by ChromaDexs patent portfolio.

FLORIDA SOUTHERN COLLEGE BREAKS GROUND ON STATE-OF-THE-ART ATHLETICS FACILITY

Retrieved on: 
Monday, August 1, 2022
Education, AACSB, NCAA Division III, View, Center, Business, Learning, Sharon, School, Highland Home, Alabama, Moccasin, Academic All-America, The Princeton Review, FSC, Athlete, Multimedia, News, Board of Trustees of Dartmouth College, U.S. News & World Report, Outline of health sciences, NCAA Division II, U.S. News & World Report Best Colleges Ranking, NCAA, Academy, Interior design, Medicine, Fortune, College, Florida Southern College, Nursing

LAKELAND, Fla., Aug. 1, 2022 /PRNewswire/ -- Florida Southern College broke ground today for the Adams Athletic Performance Center, the newest building to be constructed on campus.

Key Points: 
  • LAKELAND, Fla., Aug. 1, 2022 /PRNewswire/ -- Florida Southern College broke ground today for the Adams Athletic Performance Center, the newest building to be constructed on campus.
  • "I am confident that this project will be huge jewel in the future of Florida Southern athletics."
  • He was inducted into the Florida Southern College Athletics Hall of Fame in 2011, and has been unwavering in his support.
  • Founded in 1883, Florida Southern College is the oldest private college in the state.

Mary M. Garlock, RFC® Named to Financial Association's Board of Trustees

Retrieved on: 
Tuesday, December 7, 2021
Dream, RFC, Board of Trustees of Dartmouth College, Industry, Board, Life, Chair, Policy, MRFC, AIF, Goal, Association, Director, Solution, Happiness, Management

MIDDLETOWN, Ohio, Dec. 7, 2021 /PRNewswire-PRWeb/ --For over 23 years Mary M. Garlock, RFC, AIF has dedicated herself to her clients.

Key Points: 
  • MIDDLETOWN, Ohio, Dec. 7, 2021 /PRNewswire-PRWeb/ --For over 23 years Mary M. Garlock, RFC, AIF has dedicated herself to her clients.
  • She brings to the Trustee Board deep marketing experience fostered by some of the most notable coaches in the industry.
  • Mary will be assisting in the task at hand for the entire board - to embrace 2022 as a transition year for the Association.
  • "With Mary and our two other newly elected Trustees, I feel the IARFC has achieved this goal beyond measure.

ChromaDex Continues to Defend Strong Intellectual Property Portfolio and Plans to Appeal Judge’s Ruling in Patent Infringement Lawsuit

Retrieved on: 
Wednesday, September 15, 2021
General Health, Pharmaceutical, Health, Other Health, Elysium, Risk, District, MSJ, NAD, FDA, Securities Exchange Act of 1934, TGA, ChromaDex, Company, Board of Trustees of Dartmouth College, Securities Act of 1933, Patent, European Commission, Trustee, NR, Royal commission, Annual report, Therapeutic Goods Administration, Dartmouth College, District court, NASDAQ, Ageing, Motion, Health Canada, 1836 U.S. Patent Office fire, SEC, Research, Central District, Security (finance)

8,197,807 (the 807 patent) from the Trustees of Dartmouth College, which give ChromaDex exclusive rights to the leading NAD precursor nicotinamide riboside (NR).

Key Points: 
  • 8,197,807 (the 807 patent) from the Trustees of Dartmouth College, which give ChromaDex exclusive rights to the leading NAD precursor nicotinamide riboside (NR).
  • ChromaDex retains a strong and growing intellectual property portfolio for nicotinamide riboside, consisting of over 20 composition, process, and method of use patents for discoveries relating to NR and other NAD+ (nicotinamide adenine dinucleotide) precursors.
  • The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age.
  • ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.